IF YOU ARE FULLY VACCINATED
CDC has updated its guidance for people who are fully vaccinated. See Recommendations for Fully Vaccinated People.
IMPORTANT UPDATE FOR SCHOOLS
CDC recommends schools continue to use the current COVID-19 prevention strategies for the 2020-2021 school year. Learn more
Important update: Healthcare facilities
CDC has updated select ways to operate healthcare systems effectively in response to COVID-19 vaccination. Learn more
COVIDView: A Weekly Surveillance Summary of U.S. COVID-19 Activity

COVIDView Summary ending on September 12, 2020

COVIDView Summary ending on September 12, 2020
Updated Sept. 18, 2020

Download Weekly Summary pdf icon[13 Pages, 1.4 MB]

Key Updates for Week 37, ending September 12, 2020

Nationally, indicators that track COVID-19 activity continued to decline or remain stable (change of ≤0.1%); however, two regions reported a slight increase in the percentage of specimens testing positive for SARS-CoV-2, the virus causing COVID-19, and four regions reported a slight increase in the percent of visits for influenza-like illness (ILI) to outpatient providers or emergency departments (EDs).  Mortality attributed to COVID-19 declined but remains above the epidemic threshold.

Virus

Public Health, Commercial and Clinical Laboratories

Nationally, the percentage of respiratory specimens testing positive for SARS-CoV-2 decreased from 5.2% during week 36 to 4.8% during week 37. National percentages of specimens testing positive for SARS-CoV-2 by type of laboratory are listed.

  • Public health laboratories – decreased from 5.4% during week 36 to 4.5% during week 37
  • Clinical laboratories – increased from 5.2% during week 36 to 5.4% during week 37
  • Commercial laboratories – decreased from 5.2% during week 36 to 4.8% during week 37

Outpatient and Emergency Department Visits

Outpatient Influenza-Like Illness Network (ILINet) and National Syndromic Surveillance Program (NSSP)

Two surveillance networks are being used to track outpatient or emergency department (ED) visits for illness with symptoms compatible with COVID-19.

  • Nationally, ILI activity remains below baseline for the 22nd consecutive week and is at levels that are typical for this time of year.
  • Nationally, the percentage of visits reported for ILI by ILINet participants remained stable (change of ≤0.1%) in week 37 compared with week 36. The percentage of visits for COVID-like illness (CLI) reported to NSSP decreased for the ninth consecutive week, from 2.0% during week 36 to 1.8% during week 37.
  • Recent changes in health care seeking behavior, including increasing use of telemedicine, recommendations to limit ED visits to severe illnesses, and increased social distancing, are likely affecting both networks, making it difficult to draw conclusions at this time. Tracking these systems moving forward will give additional insight into illness related to COVID-19.

Severe Disease

Hospitalizations

Cumulative COVID-19-associated hospitalization rates since March 1, 2020, are updated weekly. The overall cumulative COVID-19 hospitalization rate is 170.4 per 100,000, with the highest rates in people aged 65 years and older (460.7 per 100,000) and 50–64 years (255.1 per 100,000).

Mortality

Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 37 is 6.2%. This is currently lower than the percentage during week 36 (9.3%); however, the percentage remains above the epidemic threshold and will likely increase as more death certificates are processed.

All data are preliminary and may change as more reports are received.

A description of the surveillance systems summarized in COVIDView, including methodology and detailed descriptions of each data component, is available on the surveillance methods page.

Key Points

  • Nationally, since mid-July, there has been an overall decreasing trend in the percentage of specimens testing positive for SARS-CoV-2 and a decreasing or stable (change of ≤0.1%) trend in the percentage of visits for ILI and CLI; however, there has been some regional variation.
  • Using combined data from the three laboratory types, the national percentage of respiratory specimens testing positive for SARS-CoV-2 with a molecular assay decreased from 5.2% during week 36 to 4.8% during week 37.
    • Regionally, the percentage of respiratory specimens testing positive for SARS-CoV-2 increased slightly in Regions 2 (New Jersey/New York/Puerto Rico) and 8 (Mountain) and decreased or remained stable in the remaining eight regions.
    • The highest percentage of specimens testing positive for SARS-CoV-2 were seen in Regions 4 (South East, 7.5%), 6 (South Central, 8.3%), and 7 (Central, 8.9%), but the percentage is decreasing in all three regions.
  • The percentage of outpatient or ED visits to ILINet providers for ILI is below baseline nationally and in all 10 regions of the country.
    • Compared with week 36, the percentage of visits for ILI during week 37 remained stable (change of ≤0.1%) nationally and decreased or was stable in seven of 10 regions. Regions 2 (New Jersey/New York/Puerto Rico), 5 (Midwest), and 6 (South Central) reported a slight increase in the percentage of visits for ILI.
  • The percentage of visits to EDs for CLI decreased nationally for the ninth consecutive week and, compared with the previous week, decreased or remained stable (change of ≤0.1%) in all 10 HHS regions. The percentage of visits to EDs for ILI was stable nationally and decreasing or stable in nine of the 10 regions. Region 7 (Central) reported a slight increase in the percentage of visits to EDs for ILI.
  • The overall cumulative COVID-19-associated hospitalization rate was 170.4 per 100,000; rates were highest in people 65 years of age and older (460.7 per 100,000) followed by people 50–64 years (255.1 per 100,000).
    • From the week ending August 1 (MMWR week 31) to the week ending September 12 (MMWR week 37), weekly hospitalization rates declined for all adult age groups. However, over this same time period, weekly rates remained steady for the pediatric age groups. Data for the most recent weeks may change as additional admissions occurring during those weeks are reported.
    • Hispanic or Latino persons, non-Hispanic American Indian or Alaska Native persons, and non-Hispanic Black persons all had age-adjusted hospitalization rates approximately 4.6 times that of non-Hispanic White persons.
  • Based on death certificate data, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 37 was 6.2%, lower than the percentage during week 36 (9.3%), but above the epidemic threshold. These percentages will likely increase as more death certificates are processed.
  • All surveillance systems aim to provide the most complete data available. Estimates from previous weeks are subject to change as data are updated with the most complete data available.

U.S. Virologic Surveillance

The number of specimens tested for SARS-CoV-2 using a molecular assay and reported to CDC by public health laboratories and a subset of clinical and commercial laboratories in the United States are summarized below. All laboratories are performing primary diagnostic functions; therefore, the percentage of specimens testing positive across laboratory types can be used to monitor overall trends in COVID-19 activity. As the outbreak progresses, it is possible that different types of laboratories will take on different roles, and the data interpretation may need to change.

Summary of Laboratory Testing Results Reported to CDC
Summary of Laboratory Testing Results Reported to CDC* Week 37
(Sept. 6–Sept. 12, 2020)
Cumulative since March 1, 2020
No. of specimens tested 1,831,880 48,727,297
          Public Health Laboratories 234,583 5,818,198
          Clinical Laboratories 129,586 5,488,128
          Commercial Laboratories 1,467,711 37,420,971
No. of positive specimens (%) 88,565 (4.8%) 4,045,085 (8.3%)
          Public Health Laboratories 10,634 (4.5%) 446,780 (7.7%)
          Clinical Laboratories 6,993 (5.4%) 335,696 (6.1%)
          Commercial Laboratories 70,938 (4.8%) 3,262,609 (8.7%)

* Commercial and clinical laboratory data represent select laboratories and do not capture all tests performed in the United States.

Public Health Laboratories

View Data Table

Clinical Laboratories

View Data Table

Commercial Laboratories

* Commercial laboratories began testing for SARS-CoV-2 in early March, but the number and geographic distribution of reporting commercial laboratories became stable enough to calculate a weekly percentage of specimens testing positive as of March 29, 2020.

View Data Table

Additional virologic surveillance information: Surveillance Methods

Outpatient/Emergency Department Illness

Two syndromic surveillance systems are being used to monitor trends in outpatient and emergency department (ED) visits that may be associated with COVID-19 illness. Each system monitors a slightly different syndrome, and together, these systems provide a more comprehensive picture of mild-to-moderate COVID-19 illness than either would individually. Both systems are currently being affected by changes in health care seeking behavior, including increased use of telemedicine, compliance with recommendations to limit ED visits to severe illnesses, and increased social distancing. These changes affect the numbers of people seeking care in the outpatient and ED settings and their reasons for doing so.

ILINet

The U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) provides data on visits for influenza-like illness (ILI) (fever [≥100F] and cough and/or sore throat) to approximately 2,600 primary care providers, emergency departments, and urgent care centers in all 50 states, Puerto Rico, the District of Columbia, and the U.S. Virgin Islands. Mild COVID-19 illness presents with symptoms similar to ILI, so ILINet is being used to track trends of mild-to-moderate COVID-19 illness and allows for comparison with prior influenza seasons.

Nationwide during week 37, 1.0% of patient visits reported through ILINet were due to ILI. This percentage is well below the national baseline of 2.4% and is typical for this time of year compared to previous influenza seasons. Compared with week 36, the percentage of visits for ILI during week 37 slightly increased overall and among the pediatric age groups (0-4 years and 5-24 years) and the 50-64 year olds.

* Age-group specific percentages should not be compared with the national baseline.

On a regional levelexternal icon, the percentage of outpatient visits for ILI ranged from 0.6% to 1.6% during week 37 and was below the region-specific baseline in all regions. Compared with week 36, the percentage increased in three of the ten regions: Regions 2 (New Jersey/New York/Puerto Rico), 5 (Midwest), and 6 (South Central).

Note: In response to the COVID-19 pandemic, new data sources are being incorporated into ILINet through the summer weeks, when lower levels of influenza and other respiratory virus circulation are typical. Starting in week 21, enrollment of new sites began, leading to increases in the number of patient visits. While all regions remain below baseline levels for ILI, these system changes should be considered when drawing conclusions from these data. Any changes in ILI due to changes in respiratory virus circulation will be highlighted here.

Overall Percentage of Visits for ILI | Age Group ILI Data

ILI Activity Levels

Data collected in ILINet are used to produce a measure of ILI activity for all 50 states, Puerto Rico, the U.S. Virgin Islands, the District of Columbia, and New York City. The mean reported percentage of visits due to ILI for the current week is compared with the mean reported during non-influenza weeks, and the activity levels correspond to the number of standard deviations below, at, or above the mean.

The number of jurisdictions at each activity level during week 37 and changes compared with the previous week are summarized in the table below and shown in the following maps. The “high” level of activity in Iowa is due to visits for ILI associated with COVID-19 activity.

ILI Activity Levels
Activity Level Number of Jurisdictions
Week 37
(Week ending
September 12, 2020)
Compared with Previous Week
Very High 0 -1
High 1 +1
Moderate 1 +1
Low 0 -1
Minimal 49 -1
Insufficient Data 3 +1

*Data collected in ILINet may disproportionally represent certain populations within a state and may not accurately depict the full picture of influenza activity for the whole state. Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of data completeness with data presented by the state likely being the more complete.

National Syndromic Surveillance Program (NSSP): Emergency Department (ED) Visits

NSSP is a collaboration among CDC, federal partners, local, and state health departments and academic and private sector partners to collect, analyze, and share electronic patient encounter data received from multiple health care settings. To track trends of potential COVID-19 visits, visits for COVID-19-like illness (CLI) (fever and cough or shortness of breath or difficulty breathing or presence of a coronavirus diagnosis code) and ILI to a subset of emergency departments in 47 states are being monitored.

Nationwide during week 37, 1.8% of ED visits captured in NSSP were due to CLI and 0.7% were due to ILI. Compared with week 36, this week the percentage of visits for CLI and the percentage of visits for ILI decreased or remained stable (changes of ≤0.1%) nationally and in 9 of 10 HHS regionsexternal icon. Region 7 (Central) saw a slight increase in ILI compared with week 36.

Additional information about medically attended outpatient and emergency department visits for ILI and CLI: Surveillance Methods

Hospitalizations

The COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) conducts population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in select counties participating in the Emerging Infections Program (EIP) and the Influenza Hospitalization Surveillance Project (IHSP).

A total of 55,544 laboratory-confirmed COVID-19-associated hospitalizations were reported by sites between March 1, 2020 and September 12, 2020. The overall cumulative hospitalization rate was 170.4 per 100,000 population. Among those aged 0–4 years, 5–17 years, 18–49 years, 50–64 years, and ≥65 years, the highest rate of hospitalization was among adults aged ≥65 years, followed by adults aged 50–64 years and adults aged 18–49 years.

Hospitalization Rates
Age Group Cumulative Rate per 100,000 Population
Overall 170.4
     0-4 years 17.3
     5-17 years 9.8
     18-49 years 116.0

  18-29 years

73.9

  30-39 years

115.6

  40-49 years

170.6
    50-64 years 255.1
    65+ years 460.7

  65-74 years

345.8

  75-84 years

546.3

  85+ years

833.1

Weekly hospitalization rates among all ages first peaked during the week ending April 18 (MMWR week 16), followed by a second peak during the week ending July 18 (MMWR week 29). From the week ending August 1 (MMWR week 31) to the week ending September 12 (MMWR week 37), weekly hospitalization rates declined for all adult age groups. However, over this same time period, weekly rates remained steady for the pediatric age groups. Data for the most recent weeks may change as additional admissions occurring during those weeks are reported.

Among the 55,544 laboratory-confirmed COVID-19-associated hospitalizations, 52,547 (94.6%) had information on race and ethnicity, while collection of race and ethnicity was still pending for 2,997 (5.4%) cases. When examining overall age-adjusted rates by race and ethnicity, Hispanic or Latino persons, non-Hispanic American Indian or Alaska Native persons, and non-Hispanic Black persons all had age-adjusted hospitalization rates approximately 4.6 times that of non-Hispanic White persons.

When examining age-stratified crude hospitalization rates by race and ethnicity, compared with non-Hispanic White persons in the same age group, crude hospitalization rates were 7.7 times higher among Hispanic or Latino persons aged 0–17 years; 8.5 times higher among Hispanic or Latino persons aged 18–49 years; 6.4 times higher among non-Hispanic American Indian or Alaska Native persons aged 50–64 years; and 3.7 times higher among non-Hispanic Black persons aged ≥65 years.

Hospitalization rates per 100,000 population
by age and race and ethnicity — COVID-NET,
March 1, 2020–September 12, 2020

Age Category

Non-Hispanic
American Indian or Alaska Native

Non-Hispanic Black

Hispanic or Latino

Non-Hispanic Asian or Pacific Islander

Non-Hispanic White

Rate1 Rate Ratio2,3 Rate1 Rate Ratio2,3 Rate1 Rate Ratio2,3 Rate1 Rate Ratio2,3 Rate1 Rate Ratio2,3
0—17 years 11.7 3.8 17.9 5.8 23.8 7.7 6.0 1.9 3.1 1
18—49 years 257.5 8.0 188.3 5.9 271.4 8.5 54.2 1.7 32.1 1
50—64 years 643.4 6.4 526.1 5.2 584.5 5.8 160.3 1.6 100.8 1
65+ years 710.8 2.5 1048.3 3.7 760.1 2.7 306.8 1.1 282.0 1
Overall rate4 (age-adjusted) 347.7 4.6 346.2 4.6 349.0 4.6 101.0 1.3 75.2 1

1 COVID-19-associated hospitalization rates by race and ethnicity are calculated using COVID-NET hospitalizations with known race and ethnicity for the numerator and NCHS bridged-race population estimates for the denominator.
2 For each age category, rate ratios are the ratios between crude hospitalization rates within each racial and ethnic group and the crude hospitalization rate among non-Hispanic white persons in the same age category.
3 The highest rate ratio in each age category is presented in bold.
4 Overall rates are adjusted to account for differences in age distributions within race and ethnicity strata in the COVID-NET catchment area; the age strata used for the adjustment include 0–17, 18–49, 50–64, and 65+ years.

Non-Hispanic Black persons and non-Hispanic White persons represented the highest proportions of hospitalizations reported to COVID-NET, followed by Hispanic or Latino, non-Hispanic Asian or Pacific Islander, and non-Hispanic American Indian or Alaska Native persons. However, some racial and ethnic groups are disproportionately represented among hospitalizations as compared with the overall population of the catchment area. Prevalence ratios were highest among non-Hispanic American Indian or Alaska Native persons, followed by non-Hispanic Black persons and Hispanic or Latino persons.

Comparison of proportions of COVID-19-associated hospitalizations by race and ethnicity, COVID-NET, March 1–September 12, 2020
Non-Hispanic American Indian or Alaska Native Non-Hispanic Black Hispanic or Latino Non-Hispanic Asian or Pacific Islander Non-Hispanic White
Proportion of hospitalized COVID-NET cases1 1.3% 32.9% 23.1% 5.1% 31.7%
Proportion of population in COVID-NET catchment 0.7% 17.9% 14.1% 8.9% 58.5%
Prevalence ratios2 1.9 1.8 1.6 0.6 0.5

1 Persons of multiple races (0.3%) or unknown race and ethnicity (5.6%) are not represented in the table but are included as part of the denominator.
2 Prevalence ratio is calculated as the ratio of the proportion of COVID-NET hospitalizations over the proportion of population in COVID-NET catchment area.

Among 11,428 hospitalized adults with information on underlying medical conditions, 90.3% had at least one reported underlying medical condition. The most commonly reported underlying medical conditions were hypertension, obesity, metabolic disease, and cardiovascular disease. Among 371 hospitalized children with information on underlying conditions, 49.1% had at least one reported underlying medical condition. The most commonly reported underlying medical conditions were obesity, neurologic disease, and asthma.

Additional data on demographics, signs and symptoms at admission, underlying conditions, interventions, outcomes and discharge diagnoses, stratified by age, sex and race and ethnicity, are available.

Additional hospitalization surveillance information: Surveillance Methods  | Additional rate data  |  Additional demographic and clinical data

Mortality Surveillance

The National Center for Health Statistics (NCHS) collects death certificate data from vital statistics offices for all deaths occurring in the United States. Based on death certificate data available on September 17, 2020, the percentage of deaths attributed to pneumonia, influenza, or COVID-19 (PIC) for week 37 is 6.2% and, while lower than the percentage during week 36 (9.3%), remains above the epidemic threshold. Percentages for recent weeks will likely increase as more death certificates are processed.

Weekly mortality surveillance data include a combination of machine coded and manually coded causes of death collected from death certificates. Percentages of deaths due to PIC are higher among manually coded records than more rapidly available machine coded records. Due to the additional time needed for manual coding, the initially reported PIC percentages may be lower than percentages calculated from final data.

*Data during recent weeks are incomplete because of the lag in time between when the death occurred and when the death certificate is completed, submitted to NCHS and processed for reporting purposes.

View Data Table

Additional NCHS mortality surveillance information: Surveillance Methods  | Provisional Death Counts for COVID-19